The use of GLP-1 receptor antagonist therapy has led to a greater reduction in colorectal cancer incidence than has been observed with aspirin.

New studies raise the possibility that GLP-1 medications beat aspirin in reducing colorectal cancer risk, and may improve outcomes for people who do develop the disease.

A daily aspirin cuts cancer, but doctors say don't reach for the bottle yet. March 20, 2012— -- A daily aspirin may cut your risk of cancer, new research suggests. But doctors advise that there's ...

GLP-1 drugs are 36% more effective than aspirin in reducing colorectal cancer risk, with fewer side effects like acute kidney ...

Your family’s history of cancer suggests a genetic component. Among genetically vulnerable individuals, low-dose aspirin appears to be useful in reducing the chance of certain malignancies (JAMA ...

Your everyday pain reliever might be doing more than just easing headaches. A major new study published in JAMA Oncology reveals that regular aspirin use could significantly lower the risk of ...

Scientists have described the “Eureka moment” when they discovered how aspirin may prevent some cancers from spreading. Their new research builds on existing evidence and suggests aspirin supports a ...

GLP-1 receptor agonists may be superior to aspirin for primary prevention of colorectal cancer, according to study results ...

Aspirin is widely known for its heart attack prevention benefits, but a new study has also linked the common drug to a reduced risk of colorectal cancer. The study analyzed data from 107,655 men and ...

Recent research from Massachusetts General Hospital and Harvard Medical School has uncovered aspirin‘s surprising protective effect against colorectal cancer, particularly among individuals with less ...

Aspirin is often touted as the wonder drug of the 20th century. Famous for its versatility—easing aches and pains, reducing fever and inflammation, preventing heart attacks and stroke—experts have ...